Unlike state Medicaid programs and the Veteran’s Administration, Medicare is prohibited from negotiating the price of prescription drugs directly with pharmaceutical makers. This prohibition is becoming increasingly problematic as more high-cost specialty medications come onto the market. Lifesaving medications for Hepatitis C—costing $84,000 per treatment and higher—are emblematic of this worrying trend. Congress should allow the Medicare program to negotiate drug prices, especially for high-cost specialty medicines.
Allow Medicare to negotiate Part D prices—especially for high-cost, specialty drugsMedicare Rights Center